Abstract submission for ESHG 2026 has closed.

Important Information on the Selection Process

All abstracts are peer-reviewed and ranked on the basis of scientific merit by experts in the category selected. The Scientific Programme Committee uses these rankings to develop the scientific sessions. Abstracts are assigned to either plenary, concurrent or poster sessions.

There are 3 types of acceptance for submissions:

  • Oral Presentation: Presenter must attend the in-person conference to present their work as an in-person oral presentation. In addition, the presentation will be live streamed, recorded and made available as on-demand content on the virtual conference platform.
  • Hybrid Poster: Presenter must attend the in-person conference to present their poster during one of the “Poster Viewing with Author” sessions. In addition, the presenter must upload a PDF version of their poster to the virtual conference platform.
  • E-Poster: Presenter must present their work virtually by uploading their poster as a PDF document to the virtual platform. Presenter must register for the conference and can decide to either attend in-person or online.

The format of acceptance will depend on the scoring result of the respective abstract and your selected preferred option.
Submitters will be informed about the format of their abstract in their e-mail acceptance notification.

IMPORTANT:

  • The presentation at the conference (in-person or online) is the condition for the publication of the abstract in the electronic supplement of the European Journal of Human Genetics. Accepted abstracts will be published in the Journal after the conference.
  • By submitting an abstract submitters agree that their personal data are being saved and used by the organiser in order to process the submission, enable the presentation at the conference and the publication of the abstract in the Journal.
  • You may be presenting author of only one paper, but co-author of any number of abstracts.
  • Multiple submissions with identical presenting authors will be automatically rejected.
  • Identical submissions from different first authors will also be automatically rejected.
  • Abstracts containing no results or structure will be rejected.

PRESS RELEASES:

Abstracts considered to be of particular interest to the media may be selected for press releases. In this case, you will be contacted by the Society’s media consultant. Please note that once your work has been published it cannot be considered as a candidate for a press release.

ESHG Abstract Submission Topics 2026 – Where does my abstract fit?

The enormous achievements in the field of Human Genetics during the last years are changing not only our understanding of genetics of diseases but also our research approaches and daily work in the clinic. Due to these new developments and insights, the traditional borders between clinical genetics, cytogenetics and molecular genetics as well as between research into monogenic and complex disorders are getting blurry. The Scientific Programme Committee (SPC) of the ESHG decided to reflect these changes in its updated abstract submission categories.

Where does my abstract fit?

The disease categories (1-12) are meant to cover all aspects of the specific conditions indicated, i.e. clinically, cytogenetically and molecularly, ranging from basic research to diagnosis and treatment.
Topic 13. Multiple Malformation/Anomalies Syndromes is meant for abstracts related to complex syndromes and cytogenetic disorders with multiple symptoms.
Topic 14. Cytogenetics, Genome Variation and Architecture is meant for abstracts discussing genomic variation and genome structure not necessarily related to a specific phenotype (e. g. splicing mechanisms, origin of ring chromosomes etc.) and abstracts related to chromosome and genome architecture studies.
Topic 15. Bioinformatics, statistical methods and AI is dedicated to abstracts related to bioinformatics, machine learning and statistical approaches in genomics and other -omics.
Topic 16. Large scale genomics (GWAS) and other -omics association studies is dedicated to abstracts presenting the genetics of complex diseases and traits, GWAS results for rare and common variation and functional follow-up studies from GWAS but also include other large-scale association studies based on other -omics datasets such as metabolomics, proteomics etc.
Topic 17. Genetic Epidemiology (e.g. Mendelian Randomization) is meant for abstracts studying the role of genomics and other -omics to personalized medicine, epidemiology, public health, and in particular improved methods for these studies including mendelian randomization studies.
Topic 18. Pharmacogenomics and Drug Repurposing is suited for studies on the genetics and genomics of (adverse) drug response, as well as repurposed or off-label use of existing drugs for (common) genetic diseases. Drug repurposing for specific rare genetic disease may be better suited in Topic 24 “Treatments for Genetic Disorders”.
Topic 19. Population Genetics and Evolutionary Genetics is meant for abstracts in population genetics and evolutionary genetics.
Topic 20. Genomics of rare diseases is meant for abstracts of broader relevance to variety of rare diseases not necessarily related to a specific phenotype (as in categories 1-12); e.g. new technologies used for rare disease research and diagnostics broadly, or cohort-level analyses for larger heterogenous groups of rare diseases.
Topic 21. Wet & dry lab improvements for diagnostics is dedicated to general aspects of technical approaches and quality control in genetic diagnostics and research.
Topic 22. Functional Genomics is for abstracts dedicated to study the biology and function of the genome, including epigenetic.
Topic 23. New Technologies shall draw attention to brand new concepts or new genomic technologies and the evaluation of their potential.
Topic 24. Treatments for Genetic Disorders is for abstracts related to novel therapeutic opportunities for genetic disorders.
Topic 25. Genetic Counselling / Services / Education covers general issues of genetic counselling, education and public services.
Topic 26. Ethical, Legal and Psychosocial Aspects in Genetics is meant for abstracts discussing psychological, ethical and legal issues of genetics.

We hope that these updated categories will enhance communication between researchers using different approaches. We are also typically using them to facilitate the selection of expert reviewers.

Topics: 

01. Cancer Genetics
02. Reproductive Genetics
03. Prenatal Genetics
04. Sensory Disorders (Eye, Ear, Pain)
05. Internal Organs and Endocrinology (Lung, Kidney, Liver, Gastrointestinal)
06. Skeletal, Connective Tissue, Ectodermal and Skin Conditions
07. Cardiovascular Disorders
08. Inborn errors of metabolism
09. Immunology and Hematopoietic System
10. Intellectual Disability
11. Neurogenetic and Psychiatric Conditions
12. Neuromuscular Conditions
13. Multiple Malformation/Anomalies Syndromes
14. Cytogenetics, Genome Variation and Architecture
15. Bioinformatics, statistical methods and AI
16. Large scale genomics (GWAS) and other -omics association studies
17. Genetic Epidemiology (e.g. Mendelian Randomization)
18. Pharmacogenomics and Drug Repurposing
19. Population Genetics and Evolutionary Genetics
20. Genomics of rare diseases
21. Wet & dry lab improvements for diagnostics
22. Functional Genomics
23. New Technologies
24. Treatments for Genetic Disorders
25. Genetic Counselling/Services/Education
26. Ethical, Legal and Psychosocial Aspects in Genetics

Affirmations

By submitting an abstract for ESHG 2026, you agree to the following terms:

  • I confirm that I will submit only one abstract as presenting author. I understand that I may be listed as co-author on other abstracts.
  • I confirm that all information in the abstract is accurate and that all listed authors have approved the submission, the presentation (in person or online), and the online publication in the European Journal of Human Genetics (EJHG).
  • I confirm that the abstract meets ethical and scientific standards and that I have checked it for spelling, author names, and other content errors before submission. I understand that ESHG does not proofread or edit abstracts and that accepted abstracts will be published as submitted.
  • I understand that any changes or corrections are possible only until the abstract submission deadline (February 16, 2026).
  • I understand that AI-based tools may be used only for language improvements (spelling, grammar, or clarity). All ideas, data, and conclusions must be the authors’ own work. The use of generative AI to create or modify scientific content is not allowed.
  • I agree that my personal data (fields marked with *) will be collected, stored, and processed according to current data protection laws (EU-GDPR 2018) and used only for organizing and managing the event.
  • I agree that my abstract, including author information, may be published in the EJHG online supplement, the ESHG conference mobile app, and on the ESHG conference website. I have read and understood the data protection information available here.
  • I understand that presentation of the abstract at the conference by a registered author is required for its publication in the EJHG online supplement.
  • I confirm that I have the necessary permission to use any patient photographs included in my presentation.
  • I confirm that the content of this submission and presentation is entirely scientific, educational, and non-commercial. It contains no product promotion, company advertisement, or material biased toward a specific commercial entity. The work represents independent research intended to advance scientific knowledge and professional practice.